Biogen Inc.

NASDAQ Global Select
Back to all articles
Bullish +72

Biogen Inc. $BIIB Shares Purchased by Banque Cantonale Vaudoise

🏦 Banque Cantonale Vaudoise boosted its Biogen stake by 129% in Q1, holding 7,928 shares valued at $1.453 million.

📈 Norges Bank and Boston Partners established new positions worth approximately $464.4 million and $302.8 million respectively in Q4.

🔼 Freedom Capital upgraded Biogen to a 'strong-buy' rating, while Guggenheim raised its price target to $260.00.

💰 Biogen reported Q1 EPS of $3.57, significantly topping the consensus estimate of $2.95.

📊 Revenue reached $2.48 billion in the quarter, beating analyst estimates of $2.29 billion by $190 million.

🚀 Year-over-year revenue growth was 1.9%, indicating continued commercial expansion in key therapeutic areas.

💵 The company maintains a robust balance sheet with a debt-to-equity ratio of 0.34 and a current ratio of 3.06.

🎯 Biogen set FY 2026 EPS guidance between $14.25 and $15.25, slightly above the analyst consensus of $13.95.

📉 The stock trades at a P/E ratio of 23.18 with a market capitalization of $31.89 billion.

🌍 Biogen operates globally with a portfolio focused on multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease.

Bullish Signals
  • Biogen reported quarterly EPS of $3.57, beating analyst estimates of $2.95 by $0.62, demonstrating strong profitability.
  • Revenue of $2.48 billion exceeded expectations of $2.29 billion, showing resilient top-line growth in a challenging market.
  • Multiple major institutional investors including Norges Bank and Boston Partners initiated significant new positions totaling over $767 million.
  • Analyst sentiment is bullish with upgrades from Freedom Capital to 'strong-buy' and Guggenheim raising its price target to $260.00.
  • The company maintains a conservative balance sheet with a low debt-to-equity ratio of 0.34 and high liquidity ratios.
  • FY 2026 guidance of $14.25-$15.25 EPS suggests management confidence in future performance above current analyst consensus.
Full Analysis
Banque Cantonale Vaudoise increased its stake in Biogen Inc. (NASDAQ:BIIB) by 129% in the first quarter, acquiring an additional 4,466 shares to hold a total of 7,928 shares valued at $1.453 million. This move joins several other institutional investors who adjusted their positions in the fourth quarter, including Norges Bank establishing a new position worth approximately $464.4 million and Boston Partners adding a stake valued at roughly $302.8 million. Analyst sentiment remains largely positive with multiple firms upgrading or reaffirming bullish ratings on Biogen stock. Cantor Fitzgerald reissued an 'overweight' rating, while Freedom Capital upgraded the stock to a 'strong-buy'. Guggenheim raised its price target from $246.00 to $260.00 and assigned a 'buy' rating. The consensus average rating is currently 'Moderate Buy' with a target price of $217.37, though individual analyst targets vary. Biogen recently reported strong quarterly financial results that exceeded analyst expectations. The company posted earnings per share (EPS) of $3.57 against a consensus estimate of $2.95, driven by revenue of $2.48 billion which beat estimates of $2.29 billion. Revenue grew 1.9% year-over-year, and the company maintains a healthy balance sheet with a debt-to-equity ratio of 0.34 and a current ratio of 3.06. The biotechnology firm, headquartered in Cambridge, Massachusetts, focuses on therapies for neurological and neurodegenerative diseases such as multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease. With a market capitalization of $31.89 billion and a price-to-earnings ratio of 23.18, Biogen has set full-year 2026 guidance between $14.25 and $15.25 EPS, slightly above the current analyst consensus expectation of $13.95.